In 1853, the perception of prostate cancer (PCa) as a rare ailment prevailed, was described
by the eminent Londoner surgeon John Adams. Rapidly forward to 2018, the landscape …

Conventional targeted drugs, RNA drugs, and radiopharmaceuticals: targeting from drivers to
passengers | ELSPublishing Menu Home Conferences Journals Books About Home Journals …

Fibroblast activation protein-α (FAPα) is highly expressed in tumor-associated cells and has
become one of the most attractive targeting sites in cancer diagnosis and therapy. To …

Currently, targeted alpha therapy (TAT) is a new therapy involving the administration of a
therapeutic drug that combines a substance of α-emitting nuclides that kill cancer cells and a …

Background We aimed to develop a publicly shared computational physiologically based
pharmacokinetic (PBPK) model to reliably simulate and analyze radiopharmaceutical …

The NOTI chelating scaffold can readily be derivatized for bioconjugation without impacting
its metal complexation/radiolabeling properties making it an attractive building block for the …

Simple Summary Prostate-specific membrane antigen (PSMA)-targeting radioligands have
been used clinically to treat metastatic prostate cancer. To deliver a sufficient radiation dose …